# A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors

> **NCT05978102** · PHASE1,PHASE2 · RECRUITING · sponsor: **The Fourth Affiliated Hospital of Zhejiang University School of Medicine** · enrollment: 183 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** STI-7349
- **DRUG:** Pembrolizumab
- **DRUG:** Standard treatment（SoC）
- **DRUG:** approved PD-1/PD-L1 inhibitors (e.g., Tislelizumab, etc.)

## Key facts

- **NCT ID:** NCT05978102
- **Lead sponsor:** The Fourth Affiliated Hospital of Zhejiang University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-23
- **Primary completion:** 2027-06
- **Final completion:** 2027-06
- **Target enrollment:** 183 (ESTIMATED)
- **Last updated:** 2025-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05978102

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05978102, "A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05978102. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*